World's Best Scientists 2026 revealed!

D-Index & Metrics

Neuroscience

D-Index
56
Citations
12360
World Ranking
4496
National Ranking
2035

Best Publications

  • Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial.

    Michael G Kaplitt;Andrew Feigin;Andrew Feigin;Chengke Tang;Helen L Fitzsimons

  • AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial

    Peter A LeWitt;Ali R Rezai;Maureen A Leehey;Steven G Ojemann

  • FDG PET in the differential diagnosis of parkinsonian disorders

    Thomas Eckert;Anna Barnes;Vijay Dhawan;Vijay Dhawan;Vijay Dhawan;Steve Frucht

  • Changes in network activity with the progression of Parkinson's disease.

    Chaorui Huang;Chengke Tang;Andrew Feigin;Martin Lesser

  • Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis

    Chris C Tang;Kathleen L Poston;Kathleen L Poston;Kathleen L Poston;Thomas Eckert;Thomas Eckert;Andrew Feigin

  • The role of radiotracer imaging in Parkinson disease

    B. Ravina;D. Eidelberg;J. E. Ahlskog;R. L. Albin

  • Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG.

    S. M. Hersch;S. Gevorkian;K. Marder;C. Moskowitz

  • A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease: No Evidence of Benefit

    M Flint Beal;David Oakes;Ira Shoulson

  • Dyskinesia after fetal cell transplantation for parkinsonism: a PET study.

    Yilong Ma;Yilong Ma;Andrew Feigin;Andrew Feigin;Vijay Dhawan;Vijay Dhawan;Masafumi Fukuda

  • Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease

    Andrew Feigin;Michael G. Kaplitt;Chengke Tang;Tanya Lin

  • Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial

    Samuel Frank;Claudia M. Testa;David Stamler;Elise Kayson

  • An examination of executive dysfunction associated with frontostriatal circuitry in Parkinson's disease

    Dennis J. Zgaljardic;Joan C. Borod;Nancy S. Foldi;Paul J. Mattis

  • Metabolic correlates of levodopa response in Parkinson's disease.

    A. Feigin;M. Fukuda;V. Dhawan;S. Przedborski

  • Metabolic Network Abnormalities in Early Huntington’s Disease: An [18F]FDG PET Study

    Andrew Feigin;Klaus L. Leenders;James R. Moeller;John Missimer

  • The metabolic anatomy of Tourette's syndrome.

    D. Eidelberg;J. R. Moeller;A. Antonini;K. Kazumata

  • Thalamic metabolism and symptom onset in preclinical Huntington's disease.

    A. Feigin;C. Tang;Y. Ma;P. Mattis

  • Abnormal metabolic networks in atypical parkinsonism.

    Thomas Eckert;Thomas Eckert;Chengke Tang;Yilong Ma;Yilong Ma;Nathaniel Brown

  • Trinucleotide repeat length and progression of illness in Huntington's disease.

    K Kieburtz;M MacDonald;C Shih;A Feigin

  • Effect of treatment with L‐dopa/carbidopa or L‐selegiline on striatal dopamine transporter SPECT imaging with [123I]β‐CIT

    Robert B. Innis;Kenneth L. Marek;Kim Sheff;Sami Zoghbi

  • Abnormal metabolic network activity in REM sleep behavior disorder

    Florian Holtbernd;Jean-François Gagnon;Ron B. Postuma;Yilong Ma

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: